Global Cell and Gene Therapy Third-Party Logistics Market Forecast to Reach USD 20.98 Billion by 2033

According to Renub Research Latest Report Cell and Gene Therapy (CGT) Third-Party Logistics Market is expected to grow from USD 8.66 billion in 2024 to USD 20.98 billion by 2033, registering a compound annual growth rate (CAGR) of 10.33%. The market’s rapid expansion is driven by technological advancements in cold chain logistics, increasing clinical trials and approvals, and the rise of personalized medicine. As healthcare evolves towards patient-specific treatments, the logistics sector is adapting to meet the growing need for specialized handling, storage, and delivery solutions.

Cell and gene therapies often involve temperature-sensitive biological materials, such as live cells and viral vectors, requiring sophisticated logistics infrastructure to maintain efficacy and safety during transportation. Third-party logistics (3PL) providers are investing in ultra-low temperature freezers, cryogenic shippers, real-time tracking systems, and advanced packaging solutions to meet these challenges, ensuring timely and secure delivery from manufacturing sites to treatment centers and even directly to patients.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Free Sample Report

Market Overview

The CGT third-party logistics market spans clinical and commercial distribution, catering to cell therapies and gene therapies across multiple therapeutic areas including oncology, neurology, cardiovascular diseases, ophthalmology, and infectious diseases. The industry’s growth is fueled by a surge in clinical trials, regulatory approvals, and the commercialization of novel therapies, creating significant demand for specialized logistics solutions.

Distribution of CGTs is complex, often involving direct-to-patient shipments or delivery to specialized treatment facilities, especially for rare or orphan diseases. Logistics providers are increasingly expected to offer flexible, scalable, and patient-centric solutions to maintain the integrity of highly sensitive products throughout the supply chain.

Growth Drivers

1. Rising Demand for Cell and Gene Therapies

The shift towards personalized medicine has driven demand for CGTs, which are tailored to a patient’s genetic profile. These therapies involve fragile biological components that must be transported under strict temperature-controlled conditions. Third-party logistics providers are essential in ensuring secure, compliant, and timely delivery, incorporating real-time monitoring systems and regulatory adherence to meet industry requirements. As personalized therapies expand, the need for advanced logistics solutions will continue to grow.

2. Increasing Investment in Biotech and Healthcare

Investment in biotechnology and the development of novel therapies has surged, prompting companies to partner with 3PL providers for global distribution. These partnerships support complex international supply chains, ensuring the safe cross-border transport of sensitive therapies. Rising biotech and healthcare investment fuels the demand for scalable logistics services capable of handling ultra-sensitive materials, thereby driving the growth of the CGT third-party logistics market.

3. Patient-Centric Logistics

The industry is increasingly focusing on patient-centric supply chains, ensuring that therapies reach patients safely and on time. 3PL providers offer door-to-door delivery, real-time shipment tracking, and transparency throughout the transit process, enhancing the patient experience. Investments in advanced packaging, temperature control, and accelerated delivery options further ensure treatment efficacy and safety. As the adoption of personalized therapies grows, patient-centric logistics becomes critical to successful therapy delivery.

Challenges in the Market

1. Packaging and Handling

Packaging CGTs is complex due to the need for precise temperature control, contamination prevention, and physical protection. Improper handling or packaging can compromise product stability, leading to reduced efficacy or safety risks. Third-party logistics providers must employ robust packaging solutions, specialized monitoring systems, and strict quality controls to mitigate these risks.

2. Temperature Sensitivity

Live cells and viral vectors used in CGTs are highly sensitive to temperature fluctuations. Maintaining constant ultra-cold conditions throughout transportation is critical to preserve biological activity. Specialized equipment, including temperature-controlled containers and real-time monitoring systems, is required. Any failure in temperature management could compromise therapy efficacy, posing risks to patient safety and treatment outcomes.

Regional Market Analysis

United States

The U.S. market is a major hub for CGT 3PL services, driven by advanced biopharmaceutical infrastructure, high investment in biotechnology, and stringent regulatory standards. 3PL providers offer temperature-controlled shipping, real-time tracking, secure storage, and compliance management. Companies like Cardinal Health, McKesson Corporation, and Cencora play a crucial role in maintaining supply chain efficiency for delicate therapies.

Germany

Germany’s biopharmaceutical sector depends heavily on specialized logistics for CAR-T cells and viral vectors, especially in biotech hubs such as Frankfurt and Düsseldorf. Strict regulatory requirements necessitate cold chain management, secure storage, and real-time monitoring. Companies like UPS, Arvato, Cryoport, and AmerisourceBergen leverage AI-driven route optimization and innovative packaging to ensure timely delivery and treatment safety.

China

China’s CGT 3PL market is rapidly expanding due to increased biotech investments and a focus on personalized medicine. Third-party logistics providers are implementing IoT-based tracking systems, ultra-cold storage, and temperature-controlled transit solutions to ensure the efficacy and safety of therapies. As China strengthens its position in the global biopharmaceutical industry, specialized logistics providers are increasingly critical to deliver transformative therapies efficiently.

Saudi Arabia

Saudi Arabia aims to become a biotechnology leader by 2040, with CGT logistics growth supported by Vision 2030 initiatives. Investments in cold chain logistics, AI, IoT, and blockchain technologies are enabling local capabilities and reducing reliance on international supply chains. Partnerships, such as between Vertex and the Ministry of Industry and Mineral Resources, aim to localize gene therapy production. Specialized 3PL services ensure safe and timely delivery to treatment facilities nationwide.

Recent Developments

Cardinal Health (Jan 2025) launched Advanced Therapy Connect, a unified ordering platform for CGTs, simplifying ordering processes and improving delivery tracking for healthcare providers.

McKesson Corporation (Oct 2024) created InspiroGene™, offering scalable 3PL solutions and commercialization support for CGTs. This initiative enhances access to life-saving therapies and ensures efficient navigation of complex supply chains.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Market Segments

By Type

Clinical

Commercial

By Product

Cell Therapies

Gene Therapies

By Therapeutic Area

Oncology

Neurology

Cardiovascular Diseases

Ophthalmology

Infectious Diseases

Others

By End-Use

Biopharmaceutical Companies

CDMOs/CMOs

Others

Regional Coverage

North America: U.S., Canada

Europe: France, Germany, Italy, Spain, U.K., Belgium, Netherlands, Turkey

Asia Pacific: China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand

Latin America: Brazil, Mexico, Argentina

Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape

Key players driving market growth with innovation, advanced infrastructure, and strategic partnerships include:

Cencora Corporation

Cardinal Health

McKesson Corporation

EVERSANA

Knipper Health

Arvato SE

DHL

Kuehne+Nagel

These companies focus on enhancing patient-centric services, regulatory compliance, temperature-sensitive logistics, and global distribution networks to capitalize on the expanding CGT market.

Future Outlook

The Global CGT Third-Party Logistics Market is poised for continued growth through 2033, driven by:

Rising adoption of personalized cell and gene therapies

Expansion of clinical trials and regulatory approvals

Growing patient-centric logistics solutions

Technological innovations in cold chain logistics, packaging, and real-time monitoring

Increased biotech and healthcare investments

As the market evolves, 3PL providers will play an increasingly crucial role in ensuring the safe, compliant, and efficient delivery of life-saving therapies. By integrating advanced technologies, AI-driven logistics, and patient-focused services, the industry is positioned to support the next generation of personalized medicine, making transformative therapies accessible worldwide.

With an estimated market value of USD 20.98 billion by 2033, CGT third-party logistics represents a high-growth segment within the biopharmaceutical supply chain, combining innovation, regulatory compliance, and patient-centric services to redefine how advanced therapies reach patients.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.